Nadine Charrière

Nadine advises clients on intellectual property and technology matters, with a focus on the life sciences and technology sectors, including AI-related contractual issues and open source. She drafts and negotiates licensing, collaboration, manufacturing, supply, distribution, and R&D agreements, and supports clients on software development and outsourcing projects. She also advises on the IP and technology aspects of M&A transactions, spin-offs, and multi-jurisdictional enforcement strategies.

• Advised Swiss and international companies on AI-related legal and commercial matters, supporting the development and implementation of AI solutions, with particular focus on IP considerations.
• Advised a major Swiss digital platform on technology, software, and IP matters, including software licensing, digital content use, and protection of brand and platform assets.
• Advised an international company on IT service arrangements covering technology services, system integration, governance of IT environments, and support for core applications and infrastructure.
• Advised a global pharmaceutical company on a number of licensing and collaboration agreements across its product portfolio.
• Advised a life sciences company on IP-driven commercial arrangements, including negotiation and refinement of licensing and collaboration agreements and support on product partnerships.
• Advised international companies on the IP and technology aspects of corporate transactions, including software, licensing framework, and open-source due diligence, and drafting of transitional IP provisions.
• Advised Swiss and international companies on enforcement actions and strategies against online and offline infringers, including trademark misuse, unfair competition, and digital brand exploitation.

Selected Public Matters

• Advised Sino Biopharm on its licensing deal with Sanofi for rovadicitinib in consideration of a total payment of up to US$1.53 billion, including an upfront payment of US$135 million plus potential development, regulatory and sales milestone payments, and up to double-digit tiered royalties.
• Advised LumApps on all IP and IT related matters in legal due diligence for merger with Beekeeper.
• Advised Arbonia on all IP related matters in the sale of its climate division to Midea Group for EUR 742 million. 
• Advised CureVac on its licensing deal with GSK for mRNA candidate vaccines for influenza and COVID-19 globally in consideration for EUR 400 million upfront and up to an additional EUR 1.05 billion in milestones as well as tiered royalties.

• Rising Star Switzerland for Intellectual Property, Managing IP, 2025-2026

• Licensing Executives Society (LES) – Member
• International Trademark Association (INTA) – INTA Bulletins Correspondent
• Institute for Intellectual Property Rights in Switzerland (INGRES) – Member
• HSG Alumni – Member
• CEMS Alumni – Member
• Swiss Bar Association
• Zurich Bar Association